Hepatitis C inhibitor tri-peptides
AssigneeBoehringer Ingelheim International GmbH
InventorsMontse Llinas-Brunet, Vida J. Gorys
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compounds of formula (1): wherein R1 is hydroxy or NHSO2R1A wherein R1A is (C1-8)alkyl, (C3-7)cycloalkyl or {(C1-6)alkyl-(C3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O—(C1-6)alkyl, amido, amino or phenyl, or R1A is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O—(C1-6) alkyl, amido, amino or phenyl; R2 is (C4-6)cycloalkyl; R3 is t-butyl or (C5-6) cycloalkyl and R4 is (C4-6)cycloalkyl; or a pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of HCV NS3 protease.
Claims36
A compound of formula (I):
- wherein R1 is hydroxy or NHSO2R1A wherein R1A is (C1-8)alkyl, (C3-7)cycloalkyl or {(C1-6)alkyl-(C3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O—(C1-6)alkyl, amido, amino or phenyl, or R1A is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O—(C1-6)alkyl, amido, amino or phenyl;
- R2 is (C4-6)cycloalkyl;
- R3 is t-butyl or (C5-6) cycloalkyl and R4 is (C4-6)cycloalkyl;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.